US-based medical device company Orthofix Medical has announced the full market launch and the first implant of Legacy Demineralized Bone Matrix (DBM).
The company said that Legacy DBM is putty for filling voids or gaps in boney defects or traumatic injuries of the spine, pelvis or extremities.
It is processed by MTF Biologics, a non-profit organisation, using specialised processing techniques that maintain the inherent growth factors present in bone.
The first patient received the implant from University Orthopedics’ chief of spine surgery, Dr Alan Daniels of Providence, Rhode Island.
Dr Alan Daniels said: “Bone healing is a dynamic process where multiple factors play an integral role in deciding which biologic best meets the individual needs of the patient to aid them on their road to recovery.
“Legacy DBM provides a cost-effective option, without compromising clinical experience or the handling needed in a bone matrix.”
According to the orthopaedic firm, Legacy DBM can be used as an extender with autograft, allograft, or bone marrow aspirate and has a putty-like consistency with pleasant handling.
Legacy DBM joins the list of recently introduced Virtuos Lyograft, Trinity Elite, FiberFuse Advanced and FiberFuse Strip allografts, and the AlloQuent structural allograft portfolio.
Orthofix offers and sells the Opus BA bioactive bone graft, OpusMg Set bone void filler, Opus One osteoconductive scaffold, and the O-Genesis graft delivery system in addition to the MTF Biologic products.
Surgeons can choose the finest alternative from this wide range of options to suit their procedural and patient needs, the company said.
Orthofix Global Spine president Kevin Kenny said: “The Legacy DBM is another example of our continued commitment to expanding biologic offerings to meet the needs of surgeons and their patients.
“In the past year alone, we have introduced five new biologics, including the Virtuos Lyograft, a first-of-its-kind, shelf-stable, and complete autograft substitute.
“We understand there are unique surgeon users for a wide range of bone-grafting options, and it is our goal to be a leading provider of these biologic offerings to our customers.”
